
  
    
      
        Background_NNP
        Identification_NNP of_IN biomarkers_NNS that_WDT provide_VBP rapid_JJ and_CC
        accessible_JJ readouts_NNS of_IN drug_NN exposure_NN ,_, activity_NN ,_, toxicity_NN or_CC
        efficacy_NN is_VBZ becoming_VBG increasingly_RB important_JJ in_IN the_DT clinical_JJ
        development_NN of_IN novel_NN molecularly_RB targeted_VBD therapeutics_NNS ._.
        Surrogate_NNP endpoints_NNS can_MD be_VB applied_VBN in_IN the_DT assessment_NN of_IN
        biological_JJ activity_NN or_CC clinical_JJ responses_NNS and_CC perhaps_RB in_IN
        selection_NN of_IN patients_NNS most_RBS likely_JJ to_TO respond_VB to_TO therapy_NN ._.
        Methodologies_NNP for_IN large-scale_JJ molecular_JJ profiling_VBG of_IN
        disease_NN tissues_NNS have_VBP been_VBN well_RB established_VBN [_NN 1_CD 2_CD 3_CD ]_NN and_CC
        have_VBP been_VBN shown_VBN to_TO be_VB of_IN utility_NN both_DT diagnostically_RB [_NN 4_CD ]_NN
        and_CC prognostically_RB [_NN 5_CD ]_NN ._. However_RB ,_, application_NN of_IN such_JJ
        approaches_NNS in_IN the_DT assessment_NN of_IN changes_NNS induced_VBN by_IN cancer_NN
        therapeutic_JJ agents_NNS in_IN solid_JJ tumors_NNS in_IN man_NN has_VBZ been_VBN hindered_VBN
        by_IN limited_JJ accessibility_NN or_CC availability_NN of_IN tumor_NN tissue_NN at_IN
        multiple_JJ time_NN points_NNS during_IN treatment_NN ._. We_PRP evaluated_VBD the_DT
        utility_NN of_IN patients_NNS '_POS blood_NN cells_NNS ,_, a_DT readily_RB accessible_JJ
        source_NN of_IN material_NN ,_, for_IN the_DT identification_NN of_IN surrogate_JJ
        molecular_JJ markers_NNS of_IN biological_JJ activity_NN of_IN SU_NNP 5416_CD ,_, a_DT small_JJ
        molecule_NN kinase_NN inhibitor_NN that_WDT is_VBZ a_DT VEGF_NNP receptor_NN (_( VEGFR_NNP )_)
        antagonist_NN with_IN anti-angiogenic_JJ properties_NNS 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN [_NN 6_CD 7_CD ]_NN ._.
        Microarray_NNP technologies_NNS such_JJ as_IN the_DT Affymetrix_NNP Genechip_NNP
        ®_NN platform_NN facilitate_VB rapid_JJ measurement_NN of_IN the_DT expression_NN
        levels_NNS of_IN thousands_NNS of_IN transcripts_NNS in_IN a_DT single_JJ experiment_NN
        and_CC allow_VB comparison_NN of_IN expression_NN patterns_NNS across_IN many_JJ
        samples_NNS [_NN 8_CD ]_NN ._. Previous_JJ reports_NNS have_VBP described_VBN gene_NN
        expression_NN profiles_NNS in_IN blood_NN that_WDT distinguish_VB patients_NNS with_IN
        relapsing-remitting_JJ multiple_JJ sclerosis_NN [_NN 9_CD ]_NN and_CC systemic_JJ
        lupus_JJ erythematosus_JJ [_NN 10_CD ]_NN from_IN healthy_JJ controls_NNS ._. We_PRP
        focused_VBD on_IN blood_NN cell_NN samples_NNS from_IN oncology_NN clinical_JJ trials_NNS
        that_WDT evaluated_VBD SU_NNP 5416_CD in_IN patients_NNS with_IN metastatic_JJ
        colorectal_NN cancer_NN ._. We_PRP reasoned_VBD that_IN peripheral_JJ blood_NN cells_NNS
        may_MD serve_VB as_IN a_DT surrogate_JJ tissue_NN since_IN VEGF_NNP receptors_NNS are_VBP
        expressed_VBN in_IN certain_JJ blood_NN cell_NN types_NNS such_JJ as_IN monocytes_NNS and_CC
        platelets_NNS [_NN 11_CD 12_CD ]_NN and_CC thus_RB signal_VB transduction_NN in_IN those_DT
        cells_NNS may_MD be_VB directly_RB impacted_VBN by_IN SU_NNP 5416_CD ;_: also_RB ,_, gene_NN
        expression_NN changes_NNS in_IN blood_NN cells_NNS caused_VBN indirectly_RB as_IN a_DT
        result_NN of_IN therapy-induced_JJ perturbations_NNS might_MD also_RB be_VB
        detected_VBN in_IN this_DT approach_NN ._.
        Subjects_NNP in_IN the_DT initial_JJ investigation_NN were_VBD participants_NNS
        in_IN an_DT open-label_JJ ,_, multicenter_NN ,_, international_JJ Phase_NN III_NNP
        study_NN in_IN which_WDT patients_NNS were_VBD randomized_JJ to_TO be_VB treated_VBN with_IN
        either_DT the_DT standard-of-care_JJ 5_CD -_: FU_NNP /_NN LV_NNP chemotherapy_NN (_( control_NN
        arm_NN )_) regimen_NN alone_RB or_CC 5_CD -_: FU_NNP /_NN LV_NNP chemotherapy_NN co-administered_JJ
        with_IN SU_NNP 5416_CD (_( treatment_NN arm_NN )_) administered_VBN twice_RB weekly_JJ via_IN
        intravenous_JJ infusion_NN at_IN a_DT dose_NN of_IN 145_CD mg_NN /_NN m_NN 2_CD (_( for_IN more_JJR
        detail_NN see_VB [_NN 13_CD 14_CD ]_NN )_) ._. Affymetrix_NNP expression_NN profiling_VBG
        technology_NN was_VBD applied_VBN to_TO RNA_NNP from_IN matched_VBN peripheral_JJ blood_NN
        mononuclear_NN cell_NN (_( PBMC_NNP )_) sample_NN pairs_NNS (_( before_IN and_CC after_IN
        treatment_NN )_) harvested_VBN from_IN subjects_NNS ,_, for_IN assessment_NN of_IN
        changes_NNS in_IN gene_NN expression_NN that_WDT might_MD correlate_VBP with_IN SU_NNP 5416_CD
        administration_NN ._. Here_RB we_PRP describe_VBP the_DT approach_NN and_CC summarize_VB
        key_JJ findings_NNS from_IN the_DT study_NN as_RB well_RB as_IN some_DT of_IN the_DT
        practical_JJ challenges_NNS that_WDT were_VBD encountered_VBN ._. A_DT set_NN of_IN
        transcripts_NNS that_IN correlated_JJ with_IN administration_NN of_IN the_DT
        SU_NNP 5416_CD regimen_NN was_VBD identified_VBN and_CC independently_RB validated_JJ
        in_IN additional_JJ clinical_JJ samples_NNS ;_: discriminant_NN analysis_NN of_IN
        change_NN in_IN levels_NNS of_IN these_DT transcripts_NNS demonstrated_VBD their_PRP$
        potential_JJ utility_NN in_IN class_NN prediction_NN ._. The_DT implications_NNS of_IN
        gene_NN expression_NN profiling_VBG applications_NNS such_JJ as_IN this_DT one_CD in_IN
        the_DT clinical_JJ development_NN of_IN novel_NN molecular_JJ therapies_NNS are_VBP
        discussed_VBN ._.
      
      
        Methods_NNP
        
          Study_NN population_NN
          Patient_NNP samples_NNS were_VBD derived_VBN from_IN 2_CD randomized_JJ ,_,
          open-label_JJ ,_, multicenter_NN Phase_NN III_NNP clinical_JJ trials_NNS
          comparing_VBG standard_NN of_IN care_NN chemotherapy_NN alone_RB or_CC combined_VBN
          with_IN SU_NNP 5416_CD in_IN patients_NNS with_IN metastatic_JJ colorectal_NN
          cancer_NN ._. In_IN both_DT trials_NNS SU_NNP 5416_CD was_VBD delivered_VBN twice_RB weekly_JJ
          at_IN a_DT dose_NN of_IN 145_CD mg_NN /_NN m_NN 2_CD via_IN I_PRP ._. V_NNP ._. infusion_NN ._. In_IN the_DT first_JJ
          trial_NN (_( designated_VBN Trial_NNP A_DT )_) ,_, the_DT standard_NN of_IN care_NN
          chemotherapy_NN consisted_VBD of_IN weekly_JJ administration_NN of_IN 5_CD -_: FU_NNP
          and_CC leucovorin_NN (_( Roswell_NNP Park_NNP regimen_NN )_) ;_: in_IN the_DT second_JJ
          trial_NN (_( designated_VBN Trial_NN B_NNP )_) ,_, the_DT standard_NN of_IN care_NN
          chemotherapy_NN consisted_VBD of_IN weekly_JJ or_CC bi-weekly_JJ
          administration_NN of_IN 5_CD -_: FU_NNP ,_, leucovorin_NN ,_, and_CC Irinotecan_NNP
          (_( CPT-_NNP 11_CD )_) ._. A_DT total_NN of_IN 23_CD pairs_NNS of_IN patient_NN samples_NNS were_VBD
          included_VBN in_IN Affymetrix_NNP microarray_NN expression_NN profiling_VBG
          analysis_NN (_( 2_CD females_NNS and_CC 9_CD males_NNS in_IN the_DT SU_NNP 5416_CD treatment_NN
          arm_NN ,_, and_CC 2_CD females_NNS and_CC 10_CD males_NNS in_IN the_DT control_NN arm_NN )_) ._. The_DT
          median_JJ patient_NN age_NN was_VBD 66_CD and_CC 65_CD years_NNS for_IN the_DT SU_NNP 5416_CD
          treatment_NN arm_NN and_CC control_NN arm_NN ,_, respectively_RB ._. For_IN RT-PCR_NNP
          verification_NN experiments_NNS ,_, samples_NNS from_IN 12_CD females_NNS and_CC 24_CD
          males_NNS from_IN the_DT SU_NNP 5416_CD treatment_NN arm_NN ,_, and_CC 14_CD females_NNS and_CC
          17_CD males_NNS from_IN the_DT control_NN arm_NN were_VBD used_VBN ._. The_DT median_JJ age_NN
          for_IN these_DT patients_NNS was_VBD 62_CD and_CC 60_CD years_NNS ,_, respectively_RB ._.
          Clinical_NNP response_NN criteria_NNS were_VBD defined_VBN according_VBG to_TO
          RECIST_NNP guidelines_NNS ;_: briefly_NN ,_, complete_JJ response_NN (_( CR_NNP )_) is_VBZ
          defined_VBN as_IN complete_JJ disappearance_NN of_IN all_DT measurable_JJ and_CC
          evaluable_JJ clinical_JJ evidence_NN of_IN cancer_NN ;_: partial_JJ response_NN
          (_( PR_NNP )_) is_VBZ defined_VBN as_IN at_IN least_JJS a_DT 50_CD %_NN reduction_NN in_IN the_DT size_NN
          of_IN all_DT measurable_JJ tumor_NN areas_NNS ,_, progressive_JJ disease_NN (_( PD_NNP )_)
          is_VBZ defined_VBN as_IN an_DT increase_NN of_IN ≥_NN 25_CD %_NN (_( compared_VBN to_TO baseline_NN
          or_CC best_JJS response_NN )_) in_IN the_DT size_NN of_IN all_DT measurable_JJ tumor_NN
          areas_NNS ;_: and_CC stable_JJ disease_NN (_( SD_NNP )_) is_VBZ defined_VBN as_IN neither_DT
          sufficient_JJ shrinkage_NN to_TO qualify_VB for_IN PR_NNP nor_CC sufficient_JJ
          increase_NN to_TO qualify_VB for_IN PD_NNP
        
        
          Patient_NNP samples_NNS
          All_DT clinical_JJ samples_NNS for_IN biomarker_NN analysis_NN were_VBD
          harvested_VBN and_CC handled_VBN in_IN accordance_NN with_IN full_JJ
          Institutional_NNP Review_NNP Board-approved_NNP protocol_NN ,_, and_CC study_NN
          participants_NNS had_VBD signed_VBN the_DT study_NN informed_VBD consent_NN prior_RB
          to_TO any_DT study-related_JJ procedures_NNS ._. All_DT blood_NN samples_NNS were_VBD
          collected_VBN into_IN Vacutainer_NNP tubes_NNS containing_VBG sodium_NN
          heparin_NN ._. Ten_CD ml_NN of_IN blood_NN was_VBD withdrawn_VBN from_IN patients_NNS
          prior_RB to_TO receiving_VBG any_DT treatment_NN on_IN day_NN 1_CD and_CC also_RB prior_RB
          to_TO dosing_VBG at_IN end_NN of_IN cycle_NN 1_CD (_( day_NN 56_CD in_IN Trial_NNP A_DT ,_, day_NN 42_CD in_IN
          Trial_NN B_NNP )_) ._. For_IN PBMC_NNP preparations_NNS ,_, blood_NN samples_NNS were_VBD
          shipped_VBN overnight_JJ at_IN ambient_NN temperature_NN to_TO a_DT central_JJ
          processing_NN facility_NN (_( Quest_NNP Diagnostics_NNPS ,_, Inc_NNP ._. ,_,
          Collegeville_NNP ,_, PA_NNP ,_, USA_NNP )_) for_IN PBMC_NNP isolation_NN via_IN Ficoll_NNP
          gradient_NN method_NN [_NN 15_CD ]_NN ._. Purified_NNP PBMCs_NNP were_VBD shipped_VBN in_IN
          RNA_NNP lysis_NNS buffer_NN (_( Clontech_NNP ,_, Palo_NNP Alto_NNP ,_, CA_NNP ,_, USA_NNP )_) to_TO SUGEN_NNP
          where_WRB isolation_NN of_IN total_JJ RNA_NNP was_VBD performed_VBN ._. For_IN Trial_NN B_NNP ,_,
          whole_JJ peripheral_JJ blood_NN samples_NNS were_VBD directly_RB frozen_VBN at_IN
          the_DT clinical_JJ sites_NNS and_CC shipped_VBN on_IN dry_JJ ice_NN to_TO SUGEN_NNP for_IN
          RNA_NNP isolation_NN ._.
        
        
          RNA_NNP sample_NN processing_NN
          Total_NNP RNA_NNP was_VBD purified_JJ from_IN PBMC_NNP samples_NNS using_VBG
          Clontech_NNP Nucleospin_NNP RNA_NNP II_NNP kit_NN reagents_NNS (_( Clontech_NNP ,_, Palo_NNP
          Alto_NNP ,_, CA_NNP )_) and_CC from_IN whole_JJ blood_NN samples_NNS using_VBG MRC_NNP TRI_NNP
          Reagent_NNP BD_NNP (_( Molecular_NNP Research_NNP Center_NNP ,_, Cincinnati_NNP ,_, OH_NNP ,_,
          USA_NNP )_) ,_, an_DT adaptation_NN of_IN the_DT Chomczynski_NNP single-step_JJ method_NN
          [_NN 16_CD ]_NN ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._.
          All_DT sample_NN preparations_NNS included_VBD a_DT treatment_NN with_IN
          RNAse-free_NNP Dnase_NNP ._. RNA_NNP yields_NNS were_VBD measured_VBN by_IN UV_NNP
          absorbance_NN and_CC RNA_NNP quality_NN was_VBD assessed_VBN by_IN agarose_NN gel_NN
          electrophoresis_NNS with_IN ethidium_NN bromide_NN staining_VBG for_IN
          visualization_NN of_IN ribosomal_JJ RNA_NNP band_NN integrity_NN ._.
        
        
          Affymetrix_NNP high-density_JJ oligonucleotide_NN microarray_NN
          analysis_NN of_IN PBMC_NNP expression_NN profiles_NNS
          In_IN general_JJ ,_, the_DT standard_JJ RNA_NNP processing_NN and_CC
          hybridization_NN protocols_NNS as_IN recommended_VBN by_IN Affymetrix_NNP
          (_( Santa_NNP Clara_NNP ,_, CA_NNP ,_, USA_NNP )_) were_VBD followed_VBN in_IN this_DT study_NN ;_: these_DT
          protocols_NNS are_VBP available_JJ in_IN the_DT Genechip_NNP ®_NN Expression_NNP
          Analysis_NNP Technical_NNP Manual_NNP ._. Yields_NNS of_IN total_JJ RNA_NNP for_IN PBMC_NNP
          samples_NNS were_VBD generally_RB low_JJ and_CC for_IN the_DT majority_NN of_IN
          patients_NNS it_PRP was_VBD not_RB possible_JJ to_TO use_VB the_DT standard_JJ amount_NN
          of_IN total_JJ RNA_NNP (_( ≥_NN 5_CD μg_NN )_) as_IN recommended_VBN in_IN the_DT standard_JJ
          protocol_NN ._. Therefore_RB a_DT double_JJ linear_JJ amplification_NN
          approach_NN [_NN 17_CD ]_NN was_VBD used_VBN in_IN the_DT generation_NN of_IN cRNA_NN for_IN
          hybridization_NN ._. In_IN these_DT experiments_NNS ,_, equal_JJ amounts_NNS of_IN
          starting_VBG material_NN were_VBD used_VBN for_IN pre-_NN and_CC post-treatment_JJ
          samples_NNS from_IN each_DT donor_NN (_( typically_RB 2_CD μg_NN )_) ._. Briefly_NNP ,_, the_DT
          protocol_NN was_VBD as_IN follows_VBZ :_: double-stranded_JJ cDNA_NN was_VBD
          synthesized_JJ from_IN total_JJ RNA_NNP ,_, with_IN Invitrogen_NNP Life_NNP
          Technologies_NNPS SuperScript_NNP Choice_NNP system_NN reagents_NNS
          (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT T_NN 7_CD -_: (_( dT_NN )_) 
          24_CD oligomer_NN was_VBD used_VBN for_IN priming_VBG
          first-strand_JJ cDNA_NN synthesis_NN ._. Double-stranded_NNP cDNA_NN product_NN
          was_VBD purified_JJ via_IN phenol-chloroform_JJ extraction_NN ,_, and_CC then_RB
          used_VBN as_IN template_NN in_IN first_JJ round_NN of_IN in_IN vitro_NN transcription_NN
          (_( IVT_NNP )_) of_IN cRNA_NN ._. The_DT IVT_NNP reaction_NN was_VBD performed_VBN with_IN
          BioArray_NNP HighYield_NNP RNA_NNP Transcript_NNP Labeling_VBG Kit_NNP
          (_( Affymetrix_NNP )_) according_VBG to_TO manufacturer_NN 's_POS protocol_NN ,_, but_CC
          with_IN substitution_NN of_IN non-biotinylated_JJ ribonucleotides_NNS for_IN
          biotinylated_JJ ribonucleotides_NNS ._. The_DT cRNA_NN product_NN was_VBD then_RB
          purified_JJ with_IN Qiagen_NNP spin_VB column_NN clean-up_JJ protocol_NN and_CC
          used_VBN as_IN template_NN in_IN second_JJ round_NN of_IN cDNA_NN synthesis_NN ._. This_DT
          second_JJ round_NN of_IN cDNA_NN synthesis_NN was_VBD similar_JJ to_TO the_DT first_JJ
          round_NN except_IN that_DT random_JJ hexamers_NNS were_VBD used_VBN in_IN priming_VBG of_IN
          first-strand_JJ synthesis_NN ,_, with_IN T_NN 7_CD -_: (_( dT_NN )_) 
          24_CD oligomer_NN priming_VBG the_DT second-strand_JJ ._.
          The_DT second_JJ round_NN of_IN IVT_NNP of_IN cRNA_NN was_VBD as_IN in_IN the_DT first_JJ round_NN
          but_CC with_IN biotinylated_JJ ribonucleotides_NNS rather_RB than_IN
          non-biotinylated_JJ ribonucleotides_NNS ._. Purified_NNP cRNA_NN was_VBD
          quantitated_JJ ,_, chemically_RB fragmented_JJ according_VBG to_TO
          Affymetrix_NNP protocol_NN ,_, and_CC then_RB hybridized_JJ overnight_JJ on_IN
          Human_NNP Genome_NNP U_NNP 95_CD A_DT Arrays_NNP (_( which_WDT contain_VBP probe_NN sets_NNS for_IN
          the_DT detection_NN of_IN approximately_RB 12_CD ,_, 600_CD transcripts_NNS )_) ._.
          Hybridized_NNP arrays_NNS were_VBD washed_VBN and_CC stained_JJ with_IN
          phycoerythrin-conjugated_JJ streptavidin_NN detection_NN chemistry_NN
          in_IN an_DT Affymetrix_NNP Fluidics_NNP station_NN ._. Images_NNP were_VBD scanned_JJ
          with_IN a_DT Hewlett-_NNP Packard_NNP GeneArray_NNP scanner_NN ._.
        
        
          Data_NNP Analysis_NNP
          Data_NNP files_NNS were_VBD generated_VBN from_IN scanned_JJ array_NN images_NNS in_IN
          the_DT Affymetrix_NNP Microarray_NNP Suite_NNP Version_NNP 4_CD ._. 0_CD program_NN ._. In_IN
          this_DT program_NN ,_, Average_NNP Difference_NNP (_( AD_NNP )_) values_NNS serve_VBP as_IN
          relative_JJ indicators_NNS of_IN the_DT expression_NN level_NN of_IN
          transcripts_NNS represented_VBD on_IN the_DT arrays_NNS ._. Average_NNP Difference_NNP
          determination_NN relies_VBZ on_IN difference_NN between_IN
          background-subtracted_JJ signal_NN from_IN perfect_JJ match_NN (_( PM_NNP )_)
          oligos_NNS and_CC corresponding_JJ mismatch_NN control_NN (_( MM_NNP )_) oligos_NNS
          within_IN a_DT probe_NN set_VBD representing_VBG a_DT given_VBN transcript_NN ._. To_TO
          enable_VB comparison_NN of_IN all_DT hybridization_NN data_NN ,_, global_JJ
          scaling_NN was_VBD applied_VBN by_IN multiplying_VBG the_DT output_NN of_IN each_DT
          experiment_NN by_IN a_DT Scaling_NNP factor_NN (_( SF_NNP )_) to_TO make_VB its_PRP$ average_JJ
          intensity_NN equal_JJ to_TO a_DT user-defined_JJ Target_NNP Intensity_NNP (_( which_WDT
          was_VBD set_VBN at_IN 1500_CD for_IN these_DT experiments_NNS )_) ._. For_IN comparisons_NNS
          between_IN time_NN points_NNS from_IN a_DT single_JJ patient_NN ,_, batch_NN files_NNS
          were_VBD generated_VBN with_IN Microarray_NNP Suite_NNP ._. These_DT files_NNS contain_VBP
          calculated_VBN fold_VB change_NN (_( FC_NNP )_) values_NNS ,_, which_WDT represent_VBP
          differential_NN expression_NN between_IN day_NN 56_CD compared_VBN to_TO
          baseline_NN ,_, and_CC also_RB Difference_NNP Calls_NNS (_( DC_NNP )_) ,_, which_WDT represent_VBP
          a_DT more_RBR conservative_JJ estimate_NN of_IN differential_NN expression_NN ,_,
          with_IN qualitative_JJ scores_NNS assigned_VBN to_TO each_DT transcript_NN
          measurement_NN according_VBG to_TO the_DT following_JJ system_NN :_: Increased_VBN
          (_( I_NN )_) ,_, Marginally_NNP Increased_VBN (_( MI_NNP )_) ,_, No_DT Change_NNP (_( NC_NNP )_) ,_,
          Marginally_NNP Decreased_NNP (_( MD_NNP )_) ,_, and_CC Decreased_NNP (_( D_NNP )_) ._.
          Subsequent_JJ data_NNS analysis_NN was_VBD performed_VBN primarily_RB with_IN
          Spotfire_NNP DecisionSite_NNP for_IN Functional_NNP Genomics_NNP software_NN
          (_( version_NN 7_CD ._. 0_CD )_) package_NN and_CC its_PRP$ Array_NNP Explorer_NNP component_NN
          (_( Spotfire_NNP ,_, Somerville_NNP ,_, MA_NNP )_) ._. Hierarchical_NNP clustering_VBG
          analysis_NN and_CC statistical_JJ comparisons_NNS were_VBD included_VBN in_IN
          this_DT step_NN ._. Further_RB refinement_NN of_IN the_DT data_NNS ,_, including_VBG
          filtering_VBG by_IN Difference_NNP Call_NNP scores_NNS ,_, was_VBD done_VBN with_IN the_DT
          Microsoft_NNP Access_NNP 97_CD database_NN analysis_NN program_NN ._.
        
        
          SYBR_NNP Green_NNP quantitative_JJ RT-PCR_NNP verification_NN of_IN
          array_NN results_NNS
          Primers_NNP were_VBD designed_VBN with_IN Primer_NNP Express_NNP 1_CD ._. 5_CD software_NN
          (_( Applied_NNP Biosystems_NNP )_) ._. In_IN all_DT cases_NNS ,_, primers_NNS were_VBD designed_VBN
          to_TO bind_NN within_IN the_DT sequence_NN represented_VBN by_IN Affymetrix_NNP
          probe_NN sets_NNS (_( target_NN sequence_NN information_NN available_JJ at_IN
          http_NN :_: /_NN /_NN www_NN ._. affymetrix_NN ._. com_NN /_NN analysis_NN /_NN index_NN ._. affx_NN )_) ._. Total_NNP RNA_NNP
          samples_NNS (_( 1_CD μg_NN )_) were_VBD reverse_VB transcribed_JJ to_TO yield_VB
          first-strand_JJ cDNA_NN using_VBG the_DT Applied_NNP Biosystems_NNP Reverse_VBP
          Transcription_NNP Reagents_NNP protocol_NN (_( Applied_NNP Biosystems_NNP ,_,
          Foster_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT reverse_JJ transcription_NN
          reactions_NNS were_VBD then_RB diluted_VBN 1_CD :_: 5_CD in_IN distilled_VBN H_NNP 
          2_CD O_NNP ._. SYBR_NNP Green_NNP PCR_NNP reactions_NNS were_VBD
          performed_VBN in_IN 96_CD -_: well_RB optical_JJ plates_NNS and_CC run_VB in_IN an_DT ABI_NNP
          PRISM_NNP ®_NN 7700_CD Sequence_NNP Detection_NNP System_NNP (_( SDS_NNP )_) machine_NN ._. For_IN
          individual_JJ reactions_NNS ,_, 10_CD μl_NN of_IN each_DT sample_NN were_VBD combined_VBN
          with_IN 15_CD μl_NN of_IN SYBR_NNP Green_NNP PCR_NNP Master_NNP Mix_NNP (_( Applied_NNP
          Biosystems_NNP )_) containing_VBG the_DT appropriate_JJ primer_NN pair_NN at_IN 350_CD
          nM_NN ._. Data_NNP were_VBD extracted_VBN and_CC amplification_NN plots_NNS generated_VBN
          with_IN ABI_NNP SDS_NNP software_NN ._. All_DT amplifications_NNS were_VBD done_VBN in_IN
          duplicate_VB and_CC threshold_NN cycle_NN (_( C_NNP 
          t_NN )_) scores_NNS were_VBD averaged_VBN for_IN
          subsequent_JJ calculations_NNS of_IN relative_JJ expression_NN values_NNS ._.
          The_DT C_NNP 
          t_NN scores_NNS represent_VBP the_DT cycle_NN number_NN at_IN
          which_WDT fluorescence_NN signal_NN (_( ΔR_NN 
          n_NN )_) crosses_VBZ an_DT arbitrary_JJ
          (_( user-defined_JJ )_) threshold_NN ._. Heat_NNP dissociation_NN curve_NN
          analysis_NN was_VBD performed_VBN after_IN each_DT SYBR_NNP Green_NNP run_VBD as_IN a_DT
          test_NN of_IN whether_IN a_DT single_JJ product_NN had_VBD been_VBN generated_VBN in_IN
          each_DT PCR_NNP reaction_NN ;_: multiple_JJ peaks_NNS in_IN the_DT dissociation_NN
          curves_NNS are_VBP indicative_JJ of_IN multiple_JJ PCR_NNP products_NNS and_CC thus_RB
          reduced_VBN specificity_NN and_CC sensitivity_NN ._.
        
        
          Quantitation_NNP and_CC statistical_JJ analysis_NN of_IN SYBR_NNP Green_NNP
          RT-PCR_NNP data_NNS
          The_DT C_NNP 
          t_NN scores_NNS for_IN genes_NNS of_IN interest_NN for_IN
          each_DT sample_NN were_VBD normalized_JJ against_IN C_NNP 
          t_NN scores_NNS for_IN the_DT corresponding_JJ
          endogenous_JJ control_NN gene_NN ,_, which_WDT was_VBD the_DT β-glucuronidase_JJ
          (_( GUS_NNP )_) gene_NN ._. Relative_NNP expression_NN for_IN day_NN 56_CD compared_VBN to_TO
          day_NN 1_CD was_VBD determined_VBN by_IN the_DT following_VBG calculation_NN ,_, as_IN
          described_VBN in_IN the_DT Applied_NNP Biosytems_NNP users_NNS bulletin_NN on_IN
          Relative_NNP Quantitation_NNP of_IN Gene_NNP Expression_NNP and_CC in_IN [_NN 18_CD ]_NN
          :_:
          Rel_NNP Exp_NNP =_SYM 2_CD -_: ΔΔCt_NN ,_,
          Where_WRB ΔΔ_NN C_NNP 
          t_NN =_SYM (_( Ct_NNP 
          Target_NNP -_: Ct_NNP 
          GUS_NNP )_) 
          day_NN 56_CD -_: (_( Ct_NNP 
          Target_NNP -_: Ct_NNP 
          GUS_NNP )_) 
          day_NN 1_CD ._. 
          The_DT relative_JJ expression_NN data_NNS for_IN a_DT selected_VBN subset_NN of_IN
          potential_JJ biomarkers_NNS were_VBD tested_VBN for_IN differences_NNS between_IN
          the_DT SU_NNP 5416_CD (_( treatment_NN )_) and_CC the_DT standard_NN of_IN care_NN (_( control_NN )_)
          arms_NNS ._. The_DT Mann-_NNP Whitney_NNP U_NNP Test_NNP with_IN a_DT critical_JJ alpha_NN level_NN
          of_IN 0_CD ._. 05_CD was_VBD used_VBN for_IN statistical_JJ significance_NN ._. Individual_JJ
          genes_NNS observed_VBD to_TO be_VB significantly_RB different_JJ by_IN
          Affymetrix_NNP analysis_NN and_CC in_IN both_DT sets_NNS of_IN SYBR_NNP Green_NNP RT-PCR_NNP
          experiments_NNS were_VBD screened_VBD as_IN potential_JJ biomarker_NN
          candidates_NNS ._. This_DT subset_NN of_IN potential_JJ biomarker_NN candidates_NNS
          was_VBD tested_VBN subsequently_RB for_IN utility_NN as_IN class_NN predictors_NNS
          to_TO discriminate_JJ between_IN the_DT SU_NNP 5416_CD and_CC the_DT standard_NN of_IN
          care_NN arms_NNS ._. Discriminant_NNP analysis_NN [_NN 19_CD ]_NN ,_, a_DT multivariate_NN
          statistical_JJ technique_NN ,_, was_VBD used_VBN for_IN this_DT purpose_NN ._. The_DT
          genes_NNS were_VBD tested_VBN individually_RB ,_, using_VBG all_DT possible_JJ
          combinations_NNS ,_, and_CC by_IN reducing_VBG dimensions_NNS (_( Principal_NN
          Component_NNP Analysis_NNP )_) in_IN order_NN to_TO determine_VB the_DT subset_NN of_IN
          genes_NNS (_( predictor_NN variables_NNS )_) that_WDT yielded_VBD highest_JJS
          classification_NN accuracy_NN ._. Cross-validation_NNP was_VBD used_VBN to_TO
          test_VB the_DT robustness_NNS of_IN classification_NN accuracy_NN ._. Results_NNS
          from_IN three_CD different_JJ cross-validations_JJ were_VBD evaluated_VBN to_TO
          select_VB the_DT best_RBS set_NN of_IN predictor_NN biomarkers_NNS :_: (_( 1_LS )_)
          jackknife_NN method_NN (_( dropping_VBG one_CD case_NN at_IN a_DT time_NN )_) ,_, (_( 2_LS )_)
          randomly_RB splitting_NN the_DT pooled_VBN data_NN into_IN two_CD halves_VBZ ,_,
          prediction_NN (_( for_IN building_NN model_NN )_) and_CC validation_NN (_( for_IN
          testing_NN model_NN )_) sets_NNS ,_, and_CC (_( 3_LS )_) using_VBG one_CD trial_NN as_IN
          prediction_NN and_CC the_DT second_JJ trial_NN as_IN validation_NN sets_NNS ,_,
          respectively_RB ._. All_DT statistical_JJ analyses_NNS were_VBD carried_VBN out_IN
          after_IN natural-log_JJ transformation_NN of_IN the_DT data_NNS ;_: SYSTAT_NNP 9_CD ._. 01_CD
          (_( SPSS_NNP ,_, Inc_NNP ._. ,_, Chicago_NNP ,_, IL_NNP ,_, USA_NNP )_) software_NN was_VBD used_VBN in_IN
          statistical_JJ analysis_NN ._.
        
      
      
        Results_NNS
        
          Affymetrix_NNP expression_NN profiling_VBG of_IN pre-_NN and_CC
          post-treatment_JJ matched_VBN PBMC_NNP samples_NNS
          Total_NNP RNA_NNP was_VBD isolated_VBN from_IN PBMC_NNP prepared_VBD from_IN
          patient_NN 's_POS blood_NN samples_NNS taken_VBN before_IN (_( pre-dose_JJ day_NN 1_LS )_) and_CC
          after_IN (_( pre-dose_JJ day_NN 56_CD )_) administration_NN of_IN SU_NNP 5416_CD or_CC
          corresponding_JJ control_NN regimen_NN in_IN a_DT Phase_NN III_NNP trial_NN ,_,
          designated_VBN as_IN Trial_NNP A_DT ._. Due_JJ to_TO typically_RB low_JJ RNA_NNP yields_NNS ,_,
          many_JJ sample_NN pairs_NNS were_VBD of_IN insufficient_JJ quality_NN for_IN
          further_JJ use_NN (_( failure_NN rate_NN of_IN at_IN least_JJS 1_CD of_IN 8_CD samples_NNS ,_, or_CC
          25_CD %_NN of_IN sample_NN pairs_NNS )_) ._. Only_RB sample_NN pairs_NNS in_IN which_WDT both_DT day_NN
          1_CD and_CC day_NN 56_CD samples_NNS RNA_NNP yields_NNS were_VBD of_IN 1_CD μg_NN or_CC greater_JJR
          were_VBD used_VBN in_IN expression_NN profiling_VBG analysis_NN ._. Samples_NNP were_VBD
          hybridized_JJ to_TO U_NNP 95_CD A_DT high-density_JJ oligonucleotide_NN arrays_NNS ._. A_DT
          total_NN of_IN 11_CD sample_NN pairs_NNS from_IN the_DT SU_NNP 5416_CD treatment_NN arm_NN
          and_CC 12_CD from_IN the_DT control_NN arm_NN were_VBD analyzed_VBN in_IN the_DT primary_JJ
          dataset_NN ._. The_DT change_NN in_IN expression_NN (_( ratio_NN of_IN day_NN 56_CD
          measurements_NNS to_TO day_NN 1_CD for_IN each_DT patient_NN as_IN calculated_VBN by_IN
          Affymetrix_NNP software_NN )_) was_VBD defined_VBN for_IN each_DT transcript_NN ;_:
          these_DT are_VBP referred_VBN to_TO as_IN fold_VB change_NN (_( FC_NNP )_) values_NNS ._. The_DT FC_NNP
          values_NNS for_IN the_DT 23_CD cases_NNS were_VBD analyzed_VBN with_IN Spotfire_NNP
          Decision_NNP Site_NNP software_NN tools_NNS ,_, to_TO compare_VB patients_NNS in_IN the_DT
          SU_NNP 5416_CD arm_NN and_CC control_NN arm_NN ._.
          A_DT t-test_JJ analysis_NN was_VBD used_VBN to_TO identify_VB transcripts_NNS
          that_WDT were_VBD statistically_RB significantly_RB different_JJ between_IN
          the_DT two_CD treatment_NN arms_NNS ._. Over_IN 100_CD genes_NNS with_IN p-values_JJ less_JJR
          than_IN 0_CD ._. 02_CD were_VBD identified_VBN ;_: however_RB ,_, because_IN there_RB are_VBP
          over_IN 12_CD ,_, 000_CD transcripts_NNS measured_VBN on_IN the_DT U_NNP 95_CD A_DT arrays_NNS ,_, some_DT
          of_IN the_DT genes_NNS would_MD potentially_RB be_VB identified_VBN by_IN chance_NN ._.
          To_TO further_VB refine_VB this_DT subset_NN of_IN genes_NNS ,_, queries_NNS based_VBN on_IN
          Difference_NNP Call_NNP (_( DC_NNP )_) status_NN were_VBD performed_VBN ;_: Difference_NNP
          Calls_NNS offer_VBP a_DT more_RBR stringent_JJ but_CC non-numerical_JJ measure_NN of_IN
          differential_NN expression_NN ,_, and_CC are_VBP derived_VBN from_IN a_DT decision_NN
          matrix_NN that_WDT weighs_VBZ comparison_NN results_NNS from_IN four_CD metrics_NNS
          used_VBN in_IN the_DT Affymetrix_NNP analysis_NN platform_NN ._. The_DT data_NNS were_VBD
          filtered_VBN to_TO identify_VB genes_NNS that_WDT were_VBD '_POS Increased_VBN '_POS (_( I_NN )_) or_CC
          '_POS Decreased_NNP '_POS (_( D_NNP )_) in_IN a_DT majority_NN of_IN the_DT SU_NNP 5416_CD arm_NN cases_NNS but_CC
          not_RB in_IN the_DT control_NN arm_NN ._. A_DT group_NN of_IN 13_CD genes_NNS that_WDT
          frequently_RB showed_VBD increased_VBN expression_NN was_VBD identified_VBN ._.
          Figure_NN 1_CD displays_NNS a_DT schema_NN of_IN the_DT DC_NNP scores_NNS assigned_VBN to_TO
          each_DT gene_NN for_IN each_DT patient_NN sample_NN pair_NN ;_: all_DT cases_NNS from_IN
          the_DT SU_NNP 5416_CD arm_NN show_NN induction_NN in_IN at_IN least_JJS 6_CD of_IN the_DT 13_CD
          genes_NNS ._. Table_NNP 1_CD lists_NNS the_DT number_NN of_IN cases_NNS in_IN each_DT arm_NN in_IN
          which_WDT an_DT '_POS Increased_VBN '_POS call_NN was_VBD assigned_VBN and_CC includes_VBZ a_DT
          brief_JJ description_NN of_IN putative_JJ functions_NNS of_IN the_DT gene_NN
          products_NNS ._. The_DT average_JJ fold_VB change_NN of_IN all_DT of_IN these_DT
          transcripts_NNS was_VBD higher_JJR in_IN the_DT SU_NNP 5416_CD arm_NN (_( the_DT lowest_JJS
          average_NN fold_VB change_NN was_VBD 2_CD ._. 6_CD for_IN hypothetical_JJ protein_NN
          FLJ_NNP 13052_CD ,_, the_DT highest_JJS was_VBD 33_CD for_IN lactoferrin_NN )_) ;_: the_DT range_NN
          of_IN fold_VB changes_NNS was_VBD also_RB broader_JJR in_IN this_DT category_NN ,_,
          presumably_RB reflecting_VBG variability_NN among_IN patients_NNS ._.
        
        
          Quantitative_NNP RT-PCR_NNP validation_NN of_IN differentially_RB
          expressed_VBD transcripts_NNS
          A_DT subset_NN of_IN these_DT transcripts_NNS was_VBD chosen_VBN for_IN
          validation_NN by_IN quantitative_JJ RT-PCR_NNP (_( qRT-PCR_JJ )_) analysis_NN ._.
          Primer_NNP sets_NNS were_VBD designed_VBN for_IN 6_CD of_IN the_DT 13_CD genes_NNS ;_: matrix_NN
          metalloproteinase-_NN 9_CD (_( MMP-_NNP 9_CD )_) ,_, thrombospondin-_NN 1_CD (_( TSP-_NNP 1_LS )_) ,_,
          CD_NNP 24_CD ,_, defensin_NN α_NN 3_CD ,_, lipocalin-_NN 2_CD (_( LNC_NNP 2_LS )_) ,_, and_CC lactoferrrin_NN
          (_( see_VB Table_NNP 2_LS )_) ._. These_DT 6_CD genes_NNS were_VBD chosen_VBN based_VBN on_IN
          potential_JJ functions_NNS of_IN encoded_JJ proteins_NNS (_( in_IN the_DT cases_NNS of_IN
          thromobospondin_NN 1_CD and_CC MMP-_NNP 9_CD ,_, these_DT have_VBP known_VBN roles_NNS in_IN
          angiogenesis_NNS )_) [_NN 20_CD 21_CD ]_NN ,_, or_CC because_IN of_IN the_DT extent_NN of_IN
          differential_NN regulation_NN between_IN treatment_NN arms_NNS ._. Also_RB ,_, the_DT
          lipocalin-_NN 2_CD gene_NN (_( LCN_NNP 2_LS )_) has_VBZ been_VBN reported_VBN to_TO be_VB inducible_JJ
          by_IN dexamethasone_NN in_IN murine_NN cells_NNS [_NN 22_CD ]_NN ;_: dexamethasone_NN
          is_VBZ one_CD of_IN the_DT premedications_NNS administered_VBN to_TO patients_NNS in_IN
          the_DT SU_NNP 5416_CD arm_NN ._.
          SYBR_NNP Green_NNP RT-PCR_NNP was_VBD used_VBN to_TO validate_NN the_DT microarray_NN
          expression_NN profiling_VBG data_NNS ._. SYBR_NNP Green_NNP is_VBZ a_DT dye_NN that_IN
          fluoresces_NNS when_WRB bound_VBN to_TO double-stranded_JJ DNA_NNP ,_, thus_RB signal_NN
          is_VBZ directly_RB proportional_JJ to_TO the_DT amount_NN of_IN product_NN formed_VBN
          during_IN PCR_NNP amplification_NN [_NN 18_CD 23_CD ]_NN ._. This_DT method_NN allows_VBZ
          rapid_JJ and_CC inexpensive_JJ comparison_NN of_IN gene_NN expression_NN
          across_IN a_DT large_JJ number_NN of_IN samples_NNS ._. The_DT qRT-PCR_JJ validation_NN
          was_VBD performed_VBN with_IN a_DT total_NN of_IN 31_CD sample_NN pairs_NNS ,_, 8_CD of_IN which_WDT
          had_VBD previously_RB been_VBN analyzed_VBN on_IN Affymetrix_NNP U_NNP 95_CD A_DT arrays_NNS
          and_CC thus_RB allowed_VBD a_DT direct_JJ comparison_NN of_IN the_DT
          correlationbetween_NN the_DT 2_CD transcript_NN profiling_VBG methods_NNS ._.
          Data_NNS for_IN each_DT gene_NN was_VBD normalized_JJ to_TO expression_NN of_IN a_DT
          housekeeping_NN gene_NN ,_, β-glucuronidase_JJ (_( GUS_NNP )_) ._. Direct_JJ
          comparison_NN of_IN SYBR_NNP Green_NNP RT-PCR_NNP results_NNS and_CC Affymetrix_NNP
          results_NNS from_IN the_DT same_JJ RNA_NNP samples_NNS (_( n_NN =_SYM 8_CD day_NN 1_CD -_: day_NN 56_CD
          pairs_NNS )_) showed_VBD an_DT overall_JJ qualitative_JJ agreement_NN (_( i_NNP ._. e_SYM ._. ,_,
          same_JJ trend_NN of_IN induction_NN or_CC no_DT change_NN detected_VBN by_IN both_DT
          methods_NNS for_IN each_DT target_NN )_) of_IN 73_CD %_NN ,_, as_IN 35_CD of_IN 48_CD comparisons_NNS
          were_VBD concordant_NN ._. This_DT number_NN may_MD be_VB an_DT underestimate_NN
          since_IN results_NNS for_IN one_CD patient_NN were_VBD inconsistent_JJ for_IN all_DT 6_CD
          transcripts_NNS ._.
          Figure_NN 2_CD summarizes_NNS the_DT results_NNS from_IN the_DT RT-PCR_NNP
          validation_NN and_CC compares_VBZ them_PRP to_TO those_DT from_IN Affymetrix_NNP
          analysis_NN ._. Mann-_NNP Whitney_NNP U_NNP test_NN comparison_NN of_IN SU_NNP 5416_CD and_CC
          control_NN results_NNS from_IN both_DT analyses_NNS indicates_VBZ that_IN three_CD
          of_IN the_DT six_CD genes_NNS displayed_VBD statistical_JJ significance_NN
          (_( p-values_JJ less_JJR than_IN 0_CD ._. 05_CD )_) based_VBN on_IN the_DT SYBR_NNP Green_NNP RT-PCR_NNP
          data_NNS (_( Table_NNP 3_LS )_) ;_: these_DT are_VBP CD_NNP 24_CD ,_, lactoferrin_NN ,_, and_CC LCN_NNP 2_CD ._.
          MMP-_NNP 9_CD exhibited_VBN a_DT p-value_JJ that_WDT was_VBD close_RB to_TO the_DT
          significance_NN cutoff_NN and_CC thus_RB was_VBD also_RB selected_VBN for_IN
          further_JJ analysis_NN ._. Defensin_NNP α_NN 3_CD and_CC TSP-_NNP 1_CD were_VBD not_RB pursued_VBN
          further_RB ._. Thus_RB ,_, four_CD of_IN the_DT six_CD initial_JJ transcripts_NNS
          selected_VBN from_IN Affymetrix_NNP expression_NN profiling_VBG were_VBD
          confirmed_VBN as_RB differentially_RB expressed_VBD using_VBG a_DT PCR-based_NNP
          approach_NN ,_, in_IN a_DT larger_JJR sample_NN set_VBN from_IN the_DT same_JJ clinical_JJ
          trial_NN ._.
        
        
          Quantitative_NNP RT-PCR_NNP validation_NN of_IN differentially_RB
          expressed_VBD transcripts_NNS with_IN samples_NNS from_IN a_DT second_JJ Phase_NN
          III_NNP SU_NNP 5416_CD trial_NN
          To_TO further_VB confirm_VB these_DT transcripts_NNS as_IN potential_JJ
          biomarkers_NNS of_IN SU_NNP 5416_CD administration_NN ,_, SYBR_NNP Green_NNP RT-PCR_NNP
          analysis_NN was_VBD carried_VBN out_IN in_IN samples_NNS from_IN a_DT second_JJ Phase_NN
          III_NNP trial_NN using_VBG SU_NNP 5416_CD (_( Trial_NN B_NNP )_) ._. This_DT trial_NN was_VBD also_RB a_DT
          randomized_JJ metastatic_JJ colorectal_NN cancer_NN study_NN ,_, comparing_VBG
          a_DT new_JJ chemotherapy_NN standard_NN of_IN care_NN ,_, 5_CD -_: FU_NNP /_NN leucovorin_NN /_NN CPT_NNP
          [_NN 24_CD 25_CD ]_NN to_TO standard_NN of_IN care_NN plus_CC SU_NNP 5416_CD ._. RNA_NNP was_VBD
          isolated_VBN from_IN patients_NNS '_POS peripheral_JJ blood_NN samples_NNS (_( rather_RB
          than_IN PBMC_NNP )_) harvested_VBN at_IN the_DT beginning_NN (_( pre-dose_JJ day_NN 1_LS )_)
          and_CC end_NN (_( day_NN 42_CD )_) of_IN cycle_NN 1_CD ._. In_IN order_NN to_TO test_VB if_IN similar_JJ
          gene_NN expression_NN changes_NNS occurred_VBD ,_, analysis_NN was_VBD performed_VBN
          on_IN 36_CD sample_NN pairs_NNS ,_, 18_CD from_IN SU_NNP 5416_CD treatment_NN arm_NN and_CC 18_CD
          from_IN control_NN arm_NN ._.
          Figure_NN 3_CD summarizes_NNS the_DT overall_JJ frequency_NN of_IN induction_NN
          of_IN 2_CD -_: fold_VB or_CC greater_JJR in_IN each_DT arm_NN of_IN the_DT trial_NN ._. It_PRP is_VBZ
          clear_JJ that_IN these_DT transcripts_NNS are_VBP more_RBR frequently_RB induced_VBN
          at_IN day_NN 42_CD of_IN treatment_NN in_IN the_DT SU_NNP 5416_CD arm_NN than_IN in_IN the_DT
          control_NN arm_NN ._. This_DT is_VBZ supported_VBN by_IN statistical_JJ analysis_NN ,_,
          as_IN indicated_VBN in_IN results_NNS of_IN the_DT Mann-_NNP Whitney_NNP U_NNP Test_NNP (_( Table_NNP
          4_LS )_) ._. A_DT visual_JJ representation_NN of_IN hierarchical_JJ clustering_VBG
          analysis_NN of_IN the_DT qRT-PCR_JJ relative_JJ expression_NN values_NNS from_IN
          both_DT trials_NNS for_IN the_DT each_DT of_IN the_DT transcripts_NNS is_VBZ displayed_VBN
          in_IN Figure_NN 4_CD ._. This_DT clustering_VBG pattern_NN displays_VBZ the_DT
          distinction_NN between_IN the_DT SU_NNP 5416_CD and_CC control_NN arms_NNS based_VBN on_IN
          relative_JJ expression_NN data_NNS ,_, and_CC also_RB indicates_VBZ further_JJ
          distinctions_NNS among_IN subsets_NNS of_IN patients_NNS as_RB well_RB as_IN the_DT
          degree_NN of_IN overlap_VB between_IN trial_NN arms_NNS in_IN the_DT clustering_VBG
          pattern_NN ._. The_DT extent_NN of_IN similarity_NN between_IN the_DT relative_JJ
          expression_NN patterns_NNS for_IN each_DT transcript_NN (_( represented_VBD in_IN
          columns_NNS )_) is_VBZ also_RB indicated_VBN ;_: the_DT pattern_NN of_IN MMP-_NNP 9_CD is_VBZ
          distinct_JJ from_IN the_DT others_NNS as_IN it_PRP appears_VBZ in_IN a_DT separate_JJ
          branch_NN in_IN the_DT dendrogram_NN structure_NN ._. A_DT table_NN containing_VBG
          the_DT raw_JJ relative_JJ expression_NN measurements_NNS included_VBN in_IN this_DT
          dataset_NN can_MD be_VB viewed_VBN in_IN Additional_JJ file_NN 1_CD ._.
          Additional_JJ file_NN
          
          Additional_JJ file_NN 1_CD
          Click_NNP here_RB for_IN file_NN
        
        
          Discriminant_NNP analysis_NN of_IN the_DT classification_NN power_NN
          of_IN candidate_NN biomarkers_NNS
          An_DT important_JJ next_JJ step_NN was_VBD to_TO test_VB whether_IN relative_JJ
          expression_NN data_NNS from_IN these_DT samples_NNS could_MD be_VB used_VBN in_IN a_DT
          predictive_JJ fashion_NN to_TO classify_VB samples_NNS to_TO the_DT appropriate_JJ
          trial_NN arm_NN ._. In_IN order_NN to_TO assess_VB this_DT ,_, discriminant_NN analysis_NN
          [_NN 19_CD ]_NN of_IN the_DT RT-PCR_NNP data_NN was_VBD performed_VBN ._. The_DT relative_JJ
          expression_NN values_NNS from_IN both_DT trials_NNS were_VBD combined_VBN into_IN a_DT
          single_JJ dataset_NN and_CC then_RB natural_JJ log-transformed_JJ to_TO reduce_VB
          the_DT scale_NN of_IN the_DT values_NNS ,_, making_VBG control_NN and_CC treated_VBN arms_NNS
          more_RBR comparable_JJ ._. When_WRB the_DT cases_NNS were_VBD pooled_VBN (_( n_NN =_SYM 67_CD )_) and_CC
          subjected_VBN to_TO classification_NN prediction_NN ,_, the_DT overall_JJ
          accuracy_NN of_IN assignment_NN to_TO the_DT appropriate_JJ trial_NN arm_NN was_VBD
          84_CD %_NN when_WRB lactoferrin_NN ,_, CD_NNP 24_CD ,_, and_CC LCN_NNP 2_CD were_VBD used_VBN as_IN the_DT
          predictor_NN gene_NN set_VBN (_( inclusion_NN of_IN MMP-_NNP 9_CD slightly_RB reduced_VBD
          the_DT accuracy_NN of_IN cross-validation_JJ )_) ._. Further_RB
          cross-validation_JJ was_VBD performed_VBN by_IN the_DT jackknife_NN method_NN
          (_( which_WDT does_VBZ a_DT series_NN of_IN predictions_NNS ,_, randomly_RB removing_VBG 1_CD
          case_NN from_IN the_DT total_VB each_DT time_NN )_) ,_, and_CC by_IN splitting_NN the_DT data_NNS
          set_VBN into_IN 2_CD random_JJ halves_VBZ (_( one_CD a_NNP '_POS training_NN '_'' set_VBN and_CC the_DT
          other_JJ a_NNP '_POS testing_NN '_'' set_VBN )_) ._.
          The_DT results_NNS from_IN each_DT of_IN these_DT steps_NNS are_VBP summarized_VBD in_IN
          Table_NNP 5_CD for_IN a_DT set_NN of_IN 3_CD of_IN the_DT 4_CD transcripts_NNS that_WDT gave_VBD the_DT
          best_JJS accuracy_NN percentage_NN ._. As_IN indicated_VBD ,_, it_PRP is_VBZ predicted_VBN
          that_IN expression_NN data_NNS from_IN these_DT 3_CD genes_NNS would_MD accurately_RB
          distinguish_VB SU_NNP 5416_CD arm_NN patients_NNS from_IN control_NN arm_NN in_IN 67_CD %_NN
          to_TO 84_CD %_NN of_IN cases_NNS ._. As_IN a_DT further_JJ test_NN ,_, the_DT dataset_NN from_IN the_DT
          first_JJ clinical_JJ trial_NN was_VBD used_VBN as_IN the_NNP '_POS training_NN '_'' set_VBN and_CC
          the_DT set_VBN from_IN the_DT second_NN as_IN the_NNP '_POS testing_NN '_'' set_VBN ,_, as_IN opposed_VBN
          to_TO pooling_VBG the_DT two_CD trials_NNS and_CC randomly_RB selecting_VBG cases_NNS ._.
          In_IN this_DT scenario_NN ,_, the_DT accuracy_NN in_IN cross-validation_JJ was_VBD
          86_CD %_NN and_CC 77_CD %_NN for_IN the_DT training_NN and_CC testing_NN set_VBD ,_,
          respectively_RB ._. This_DT suggests_VBZ that_IN results_NNS derived_VBN from_IN one_CD
          trial_NN might_MD be_VB applied_VBN prospectively_RB in_IN analysis_NN of_IN
          subsequent_JJ similar_JJ trials_NNS ._.
        
      
      
        Discussion_NNP
        Large-scale_NNP gene_NN expression_NN analysis_NN was_VBD applied_VBN to_TO
        blood_NN RNA_NNP samples_NNS from_IN a_DT clinical_JJ trial_NN of_IN the_DT signal_NN
        transduction_NN inhibitor_NN SU_NNP 5416_CD to_TO investigate_VB changes_NNS in_IN
        gene_NN expression_NN that_WDT might_MD correlate_VBP with_IN exposure_NN to_TO this_DT
        experimental_JJ cancer_NN therapy_NN ._. A_DT set_NN of_IN 4_CD transcripts_NNS (_( CD_NNP 24_CD ,_,
        lactoferrin_NN ,_, LCN_NNP 2_CD ,_, and_CC MMP-_NNP 9_CD )_) was_VBD identified_VBN ,_, whose_WP$
        expression_NN was_VBD significantly_RB induced_VBN at_IN the_DT end_NN of_IN one_CD
        treatment_NN cycle_NN relative_JJ to_TO baseline_NN following_VBG SU_NNP 5416_CD
        administration_NN ._. Discriminant_NNP analysis_NN indicated_VBD that_IN
        changes_NNS in_IN expression_NN of_IN these_DT transcripts_NNS predicted_VBD the_DT
        trial_NN arm_NN to_TO which_WDT a_DT patient_NN belonged_VBD with_IN accuracy_NN as_RB high_JJ
        as_IN 80_CD %_NN ._.
        This_DT work_NN represents_VBZ a_DT novel_NN approach_NN to_TO clinical_JJ
        biomarker_NN discovery_NN wherein_WRB expression_NN profiling_VBG of_IN
        patients_NNS '_POS blood_NN cell_NN RNA_NNP is_VBZ utilized_JJ as_IN a_DT surrogate_JJ readout_NN
        of_IN dynamic_JJ changes_NNS occurring_VBG in_IN patients_NNS bearing_VBG solid_JJ
        tumors_NNS ._. A_DT recent_JJ report_NN describes_VBZ an_DT expression_NN profiling_VBG
        approach_NN as_IN applied_VBN to_TO bone_NN marrow_NN samples_NNS before_IN and_CC after_IN
        treatment_NN with_IN the_DT tyrosine_NN kinase_NN inhibitor_NN STI-_NNP 571_CD in_IN
        patients_NNS with_IN acute_JJ lymphoblastic_JJ leukemia_NN [_NN 26_CD ]_NN ._. This_DT
        work_NN clearly_RB demonstrates_VBZ utility_NN of_IN the_DT approach_NN in_IN
        investigation_NN of_IN drug-resistance_JJ development_NN in_IN
        hematological_JJ malignancies_NNS ._. However_RB ,_, extending_VBG similar_JJ
        approaches_NNS to_TO solid_JJ tumor_NN oncology_NN is_VBZ technically_RB and_CC
        clinically_RB challenging_VBG due_JJ to_TO relative_JJ inaccessibility_NN of_IN
        tumor_NN tissue_NN and_CC difficulties_NNS in_IN obtaining_VBG samples_NNS at_IN
        multiple_JJ time_NN points_NNS ._. In_IN our_PRP$ investigation_NN ,_, a_DT relatively_RB
        small_JJ number_NN of_IN transcript_NN level_NN changes_NNS were_VBD identified_VBN
        that_WDT were_VBD specific_JJ to_TO patients_NNS receiving_VBG an_DT SU_NNP 5416_CD dosing_VBG
        regimen_NN ,_, and_CC 4_CD of_IN these_DT were_VBD independently_RB verified_VBN in_IN a_DT
        larger_JJR sample_NN set_VBN ._. Inter-individual_NNP variation_NN and_CC
        heterogeneity_NN of_IN response_NN are_VBP two_CD variables_NNS that_WDT have_VBP
        likely_RB impacted_VBN this_DT dataset_NN ,_, and_CC it_PRP is_VBZ possible_JJ that_IN a_DT
        greater_JJR number_NN of_IN statistically_RB significant_JJ changes_NNS might_MD
        be_VB observed_VBN if_IN a_DT larger_JJR group_NN of_IN patients_NNS were_VBD used_VBN in_IN the_DT
        initial_JJ Affymetrix_NNP analysis_NN ._. Further_RB ,_, inclusion_NN of_IN more_JJR
        than_IN a_DT single_JJ sampling_VBG timepoint_NN after_IN initiation_NN of_IN
        treatment_NN would_MD also_RB likely_JJ be_VB informative_JJ in_IN future_JJ
        studies_NNS ,_, and_CC presumably_RB provide_VB a_DT window_NN to_TO more_RBR acute_JJ
        physiological_JJ changes_NNS triggered_VBN by_IN drug_NN exposure_NN ._. Also_RB ,_, a_DT
        relatively_RB stringent_JJ criterion_NN for_IN significance_NN -_: the_DT
        Affymetrix_NNP Difference_NNP Call_NNP -_: was_VBD used_VBN in_IN the_DT selection_NN of_IN
        transcripts_NNS that_WDT were_VBD expressed_VBN differently_RB in_IN each_DT trial_NN
        arm_NN ._. Mining_NNP the_DT dataset_NN with_IN other_JJ analytical_JJ approaches_NNS
        might_MD lead_VB to_TO a_DT different_JJ set_NN of_IN potential_JJ biomarkers_NNS ._.
        However_RB ,_, it_PRP is_VBZ worth_JJ noting_VBG that_IN we_PRP have_VBP retrospectively_RB
        applied_VBN Significance_NN Analysis_NNP of_IN Microarrays_NNP ,_, or_CC SAM_NNP ,_, [_NN 27_CD
        ]_NN to_TO the_DT Affymetrix_NNP dataset_NN :_: 3_CD of_IN the_DT 10_CD most_RBS significant_JJ
        genes_NNS identified_VBN by_IN that_DT method_NN were_VBD among_IN the_DT 4_CD that_WDT were_VBD
        verified_VBN by_IN RT-PCR_NNP (_( LCN_NNP 2_CD ,_, CD_NNP 24_CD ,_, and_CC lactoferrin_NN )_) ,_, with_IN
        MMP-_NNP 9_CD ranked_VBD sixteenth_NN ._. All_DT of_IN the_DT transcripts_NNS listed_VBN in_IN
        Table_NNP 1_CD were_VBD included_VBN among_IN the_DT 27_CD most_RBS significant_JJ ,_, with_IN
        the_DT exception_NN of_IN thrombospondin_NN (_( ranked_VBD 50_CD th_NN )_) ._.
        Independent_NNP quantitative_JJ RT-PCR_NNP verification_NN of_IN initial_JJ
        array_NN hybridization_NN results_NNS was_VBD performed_VBN on_IN larger_JJR sample_NN
        populations_NNS obtained_VBN from_IN two_CD conceptually_RB similar_JJ Phase_NN
        III_NNP clinical_JJ trials_NNS that_WDT used_VBD SU_NNP 5416_CD ._. Further_RB exploration_NN
        of_IN the_DT differential_NN expression_NN data_NNS for_IN these_DT 4_CD transcripts_NNS
        suggests_VBZ that_IN differences_NNS in_IN expression_NN are_VBP relatively_RB
        robust_JJ and_CC adequate_JJ to_TO allow_VB classification_NN of_IN patients_NNS
        into_IN appropriate_JJ arms_NNS of_IN the_DT trial_NN ,_, with_IN an_DT expected_VBN
        accuracy_NN of_IN greater_JJR than_IN 70_CD %_NN ._. It_PRP must_MD be_VB stressed_VBN that_IN the_DT
        subject_JJ population_NN size_NN in_IN this_DT qRT-PCR_JJ study_NN is_VBZ not_RB large_JJ
        (_( n_NN =_SYM 67_CD )_) ;_: however_RB ,_, the_DT results_NNS are_VBP encouraging_VBG given_VBN the_DT
        challenges_NNS of_IN working_VBG with_IN samples_NNS from_IN these_DT two_CD large_JJ
        multicenter_NN clinical_JJ trials_NNS ._.
        These_DT four_CD transcripts_NNS are_VBP considered_VBN to_TO be_VB biomarkers_NNS
        of_IN the_DT SU_NNP 5416_CD administration_NN regimen_NN rather_RB than_IN activity_NN
        of_IN SU_NNP 5416_CD specifically_RB ;_: with_IN the_DT available_JJ samples_NNS we_PRP could_MD
        not_RB exclude_VB the_DT possibility_NN that_WDT altered_VBD gene_NN expression_NN
        resulted_VBD from_IN exposure_NN to_TO the_DT administration_NN vehicle_NN
        (_( Cremophor_NNP )_) or_CC the_DT concomitant_NN premedications_NNS
        (_( dexamethasone_NN and_CC H_NNP 1_CD -_: and_CC H_NNP 2_CD -_: blocker_NN antihistamines_NNS )_)
        rather_RB than_IN SU_NNP 5416_CD ._. The_DT mouse_NN homologue_NN of_IN one_CD of_IN the_DT
        candidate_NN biomarkers_NNS ,_, LNC_NNP 2_CD ,_, has_VBZ been_VBN shown_VBN to_TO be_VB regulated_VBN
        at_IN the_DT transcriptional_NN level_NN by_IN dexamethasone_NN in_IN murine_NN
        cells_NNS [_NN 22_CD ]_NN ._. However_RB ,_, there_EX is_VBZ no_DT published_VBN evidence_NN that_IN
        the_DT human_JJ LCN_NNP 2_CD gene_NN is_VBZ likewise_RB dexamethasone-inducible_JJ ,_,
        and_CC there_EX is_VBZ no_DT description_NN of_IN glucocorticoid-responsive_JJ
        elements_NNS in_IN the_DT 5_CD '_POS regulatory_JJ region_NN of_IN the_DT human_JJ LCN_NNP 2_CD gene_NN
        [_NN 28_CD ]_NN ._. Further_RB ,_, preliminary_JJ investigation_NN in_IN our_PRP$
        laboratory_NN ,_, using_VBG 
        in_IN vitro_NN cultures_NNS of_IN purified_JJ PBMCs_NNP
        from_IN healthy_JJ volunteers_NNS ,_, indicates_VBZ that_IN neither_DT the_DT LCN_NNP 2_CD
        gene_NN nor_CC any_DT of_IN the_DT other_JJ 3_CD transcripts_NNS is_VBZ directly_RB
        inducible_JJ by_IN acute_JJ treatment_NN with_IN either_DT SU_NNP 5416_CD or_CC
        dexamethasone_NN (_( data_NNS not_RB shown_VBN )_) ._. The_DT biological_JJ connection_NN
        between_IN expression_NN of_IN these_DT four_CD transcripts_NNS and_CC this_DT
        therapy_NN regimen_NN remains_VBZ to_TO be_VB further_JJ elucidated_JJ ._. However_RB ,_,
        the_DT fact_NN that_IN SU_NNP 5416_CD is_VBZ an_DT inhibitor_NN of_IN VEGF-mediated_NNP
        angiogenesis_NNS may_MD be_VB of_IN relevance_NN to_TO the_DT expression_NN of_IN MMP-_NNP 9_CD
        mRNA_NN ,_, as_IN the_DT gene_NN encodes_NNS a_DT well-characterized_JJ enzyme_NN with_IN
        roles_NNS in_IN angiogenesis_NNS and_CC tissue_NN remodeling_NN ._. Also_RB
        noteworthy_JJ is_VBZ a_DT report_NN describing_VBG bovine_JJ lactoferrin_NN as_IN an_DT
        inhibitor_NN of_IN VEGF-mediated_NNP angiogenesis_NNS in_IN a_DT rat_NN model_NN [_NN 29_CD
        ]_NN ._. Intriguingly_NNP ,_, a_DT recent_JJ report_NN has_VBZ identified_VBN a_DT high_JJ
        molecular_JJ weight_NN urinary_JJ MMP_NNP to_TO be_VB a_DT complex_NN of_IN MMP-_NNP 9_CD and_CC
        LCN_NNP 2_CD (_( herein_NN referred_VBD to_TO as_IN neutrophil_NN
        gelatinase-associated_JJ lipocalin_NN ,_, or_CC NGAL_NNP )_) proteins_NNS [_NN 30_CD ]_NN ._.
        Such_JJ urinary_JJ MMP_NNP complexes_NNS have_VBP been_VBN described_VBN as_IN useful_JJ
        markers_NNS for_IN cancer_NN diagnosis_NN and_CC prognosis_NN ._. The_DT relevance_NN
        of_IN the_DT MMP-_NNP 9_CD /_NN NGAL_NNP protein_NN complex_JJ to_TO the_DT observed_VBD changes_NNS
        in_IN the_DT levels_NNS of_IN their_PRP$ transcripts_NNS in_IN blood_NN cells_NNS remains_VBZ
        to_TO be_VB determined_VBN ._.
        Investigation_NNP of_IN expression_NN patterns_NNS of_IN these_DT four_CD genes_NNS
        in_IN samples_NNS from_IN clinical_JJ trials_NNS designed_VBN to_TO test_VB other_JJ
        angiogenesis_NNS inhibitors_NNS will_MD allow_VB further_JJ examination_NN of_IN
        their_PRP$ validity_NN as_IN biomarkers_NNS of_IN mechanism_NN or_CC drug_NN exposure_NN ._.
        This_DT approach_NN may_MD also_RB be_VB useful_JJ in_IN the_DT identification_NN of_IN
        biomarkers_NNS of_IN clinical_JJ response_NN ._. Our_PRP$ initial_JJ analysis_NN has_VBZ
        not_RB yielded_VBN a_DT definitive_JJ set_NN of_IN gene_NN expression_NN changes_NNS ,_, in_IN
        PBMC_NNP samples_NNS ,_, that_WDT are_VBP correlated_JJ with_IN objective_NN response_NN
        at_IN end_NN of_IN first_JJ cycle_NN ;_: this_DT may_MD be_VB related_VBN to_TO a_DT limited_JJ
        sample_NN size_NN or_CC features_NNS of_IN the_DT specific_JJ trial_NN design_NN and_CC
        patient_NN population_NN ._. Also_RB ,_, as_RB previously_RB discussed_VBN ,_, it_PRP may_MD
        be_VB essential_JJ to_TO profile_VB samples_NNS harvested_VBN at_IN multiple_JJ time_NN
        points_NNS during_IN the_DT course_NN of_IN therapy_NN in_IN order_NN to_TO fully_RB
        capture_VB the_DT variability_NN and_CC extent_NN of_IN dynamic_JJ responses_NNS
        specific_JJ to_TO a_DT given_VBN therapy_NN ._. However_RB ,_, the_DT methodology_NN will_MD
        be_VB applied_VBN to_TO subsequent_JJ clinical_JJ trials_NNS involving_VBG other_JJ
        anti-angiogenesis_JJ agents_NNS and_CC molecularly_RB targeted_VBN
        therapeutics_NNS ._.
        Additionally_RB and_CC importantly_RB ,_, improvements_NNS in_IN reagents_NNS
        available_JJ for_IN storage_NN and_CC purification_NN of_IN RNA_NNP from_IN clinical_JJ
        blood_NN samples_NNS should_MD also_RB enhance_VB quality_NN of_IN specimens_NNS ,_,
        especially_RB in_IN cases_NNS where_WRB specimens_NNS are_VBP initially_RB harvested_VBN
        at_IN multiple_JJ clinical_JJ sites_NNS ;_: the_DT recently_RB introduced_VBN PAXgene_NNP
        blood_NN RNA_NNP stabilization_NN reagent_NN is_VBZ an_DT example_NN of_IN such_JJ
        improvement_NN [_NN 31_CD ]_NN ._. The_DT analysis_NN of_IN whole_JJ blood_NN rather_RB
        than_IN purified_JJ PBMC_NNP as_IN surrogate_JJ specimens_NNS in_IN future_JJ studies_NNS
        may_MD also_RB minimize_VB variations_NNS due_JJ to_TO sample_NN handling_NN and_CC
        processing_VBG ._. Nevertheless_RB ,_, the_DT results_NNS described_VBD here_RB
        demonstrate_VB that_IN human_JJ blood_NN samples_NNS can_MD serve_VB as_IN surrogate_JJ
        specimens_NNS for_IN biomarker_NN investigations_NNS in_IN cancer_NN patients_NNS
        and_CC imply_VBP that_IN large-scale_JJ gene_NN expression_NN analysis_NN may_MD be_VB
        a_DT useful_JJ approach_NN for_IN characterization_NN of_IN drug_NN activity_NN
        from_IN clinical_JJ trial_NN samples_NNS ._. This_DT expression_NN profiling_VBG
        approach_NN might_MD also_RB both_DT lead_VB to_TO and_CC be_VB enhanced_VBN by_IN
        improvements_NNS in_IN oncology_NN trial_NN design_NN ,_, such_JJ as_IN more_RBR
        rational_JJ and_CC tailored_VBN selection_NN of_IN indications_NNS or_CC
        individuals_NNS that_WDT are_VBP most_RBS likely_JJ to_TO be_VB responsive_JJ to_TO a_DT
        given_VBN molecularly_RB targeted_VBN therapy_NN ._.
      
      
        Conclusions_NNP
        Large-scale_NNP gene_NN expression_NN profiling_VBG has_VBZ been_VBN applied_VBN
        to_TO peripheral_JJ blood_NN cells_NNS harvested_VBN before_IN and_CC after_IN
        treatment_NN from_IN patients_NNS participating_VBG in_IN a_DT Phase_NN III_NNP
        clinical_JJ trial_NN of_IN SU_NNP 5416_CD ._. Four_CD transcripts_NNS were_VBD identified_VBN
        as_IN potential_JJ biomarkers_NNS of_IN SU_NNP 5416_CD administration_NN and_CC
        verified_VBN using_VBG a_DT qRT-PCR_JJ approach_NN ._. Discriminant_NNP analysis_NN
        indicated_VBD that_IN expression_NN profiles_NNS of_IN these_DT transcripts_NNS
        could_MD be_VB used_VBN to_TO predict_VB the_DT trial_NN arm_NN to_TO which_WDT patients_NNS
        belonged_VBD ._. These_DT results_NNS suggest_VBP that_DT expression_NN profiling_VBG
        of_IN peripheral_JJ blood_NN cells_NNS is_VBZ a_DT valid_JJ surrogate_JJ approach_NN for_IN
        biomarker_NN discovery_NN in_IN oncology_NN clinical_JJ trials_NNS ._.
      
      
        Competing_VBG interests_NNS
        All_DT authors_NNS are_VBP employed_VBN by_IN SUGEN_NNP ,_, Inc_NNP ._.
      
      
        Authors_NNP '_'' contributions_NNS
        S_NNP ._. DePrimo_NNP planned_VBD and_CC performed_VBN gene_NN expression_NN
        profiling_VBG laboratory_NN work_NN and_CC data_NNS analysis_NN ,_, and_CC drafted_VBD
        the_DT manuscript_NN ;_: L_NNP ._. Wong_NNP performed_VBD gene_NN expression_NN profiling_VBG
        laboratory_NN work_NN and_CC aided_VBN in_IN clinical_JJ sample_NN tracking_VBG ;_: D_NNP ._.
        Khatry_NNP performed_VBD statistical_JJ data_NNS analysis_NN and_CC discriminant_NN
        analysis_NN ;_: S_NNP ._. Nicholas_NNP performed_VBD curation_NN and_CC tracking_NN of_IN
        clinical_JJ samples_NNS ;_: W_NNP ._. Manning_NNP participated_VBD in_IN the_DT
        supervision_NN and_CC coordination_NN of_IN the_DT study_NN and_CC manuscript_NN
        preparation_NN ;_: B_NNP ._. Smolich_NNP contributed_VBD to_TO the_DT conception_NN ,_,
        design_NN and_CC coordination_NN of_IN the_DT study_NN ;_: A_DT ._. O_NNP '_POS Farrell_NNP initiated_VBD
        expression_NN profiling_VBG laboratory_NN work_NN and_CC manuscript_NN
        preparation_NN and_CC participated_VBD in_IN the_DT design_NN ,_, supervision_NN ,_,
        and_CC coordination_NN of_IN the_DT study_NN ;_: J_NNP ._. Cherrington_NNP contributed_VBD
        to_TO the_DT conception_NN ,_, design_NN ,_, coordination_NN ,_, and_CC guidance_NN of_IN
        the_DT study_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ
        manuscript_NN ._.
      
    
  
